Figure 1. Effect of IFN-α on PB or BM... | American Society of Hematology

Figure 1.

$Effect of IFN-α on PB or BM cells in Jak2V617F and Jak2V617F;Tyk2−/− mice. (A) PB cell counts after treatment with ropeg-IFN-α. PBS or 600 ng of ropeg-IFN-α was injected weekly for 8 weeks. WT mice (n = 6 per PBS, and n = 7 per ropeg-IFN-α treatment); Tyk2−/− mice (n = 6 per PBS, and n = 6 per ropeg-IFN-α treatment); Jak2V617F mice (n = 9 per PBS, and n = 7 per ropeg-IFN-α treatment); and Jak2V617F;Tyk2−/− mice (n = 11 per PBS, and n = 12 per ropeg-IFN-α treatment). At 48 hours after the last treatment, PB leukocyte count, Hb level, and platelet count were measured. Data were presented as mean ± standard deviation (SD). (B) Changes in PB hematopoietic compartments after treatment with ropeg-IFN-α. The fold change of each Mac1+Gr1+ cell, B220+ cell, and CD3+ cell fraction in the PB from Jak2V617F and Jak2V617F;Tyk2−/− mice was presented as the comparison with those in the PB from WT mice treated with PBS. (C) BM progenitors after 8 weeks of treatment with ropeg-IFN-α. At 48 hours after the last treatment, the proportion of GMPs, MEPs, MKPs, and CD41+ cells in the BM was analyzed. Data are presented as mean ± SD. (D) The proportion of LT-HSCs in the BM after treatment with ropeg-IFN-α. A reduction in LT-HSC proportions was observed in ropeg-IFN-α–treated Jak2V617F mice, whereas no reduction was observed in Jak2V617F;Tyk2−/− mice. Data are presented as mean ± SD. (E) Analysis of the number of LT-HSCs after 8 weeks of treatment with ropeg-IFN-α. The total number of LT-HSCs in 2 femurs and 1 tibia is shown. Data are presented as mean ± SD. Statistical significance was determined by the Tukey test after 1-way analysis of variance (ANOVA). ∗P < .05; ∗∗P < .01; and ∗∗∗P < .001. WBC, white blood cell; Hb, hemoglobin; Plt, platelet; n.s., not significant.$

Effect of IFN-α on PB or BM cells in Jak2V617F and Jak2V617F;Tyk2^−/− mice. (A) PB cell counts after treatment with ropeg-IFN-α. PBS or 600 ng of ropeg-IFN-α was injected weekly for 8 weeks. WT mice (n = 6 per PBS, and n = 7 per ropeg-IFN-α treatment); Tyk2^−/− mice (n = 6 per PBS, and n = 6 per ropeg-IFN-α treatment); Jak2V617F mice (n = 9 per PBS, and n = 7 per ropeg-IFN-α treatment); and Jak2V617F;Tyk2^−/− mice (n = 11 per PBS, and n = 12 per ropeg-IFN-α treatment). At 48 hours after the last treatment, PB leukocyte count, Hb level, and platelet count were measured. Data were presented as mean ± standard deviation (SD). (B) Changes in PB hematopoietic compartments after treatment with ropeg-IFN-α. The fold change of each Mac1⁺Gr1⁺ cell, B220⁺ cell, and CD3⁺ cell fraction in the PB from Jak2V617F and Jak2V617F;Tyk2^−/− mice was presented as the comparison with those in the PB from WT mice treated with PBS. (C) BM progenitors after 8 weeks of treatment with ropeg-IFN-α. At 48 hours after the last treatment, the proportion of GMPs, MEPs, MKPs, and CD41⁺ cells in the BM was analyzed. Data are presented as mean ± SD. (D) The proportion of LT-HSCs in the BM after treatment with ropeg-IFN-α. A reduction in LT-HSC proportions was observed in ropeg-IFN-α–treated Jak2V617F mice, whereas no reduction was observed in Jak2V617F;Tyk2^−/− mice. Data are presented as mean ± SD. (E) Analysis of the number of LT-HSCs after 8 weeks of treatment with ropeg-IFN-α. The total number of LT-HSCs in 2 femurs and 1 tibia is shown. Data are presented as mean ± SD. Statistical significance was determined by the Tukey test after 1-way analysis of variance (ANOVA). ∗P < .05; ∗∗P < .01; and ∗∗∗P < .001. WBC, white blood cell; Hb, hemoglobin; Plt, platelet; n.s., not significant.

This Feature Is Available To Subscribers Only